Ceapro Inc V.CZO

S&P Biotech ETF

[prophetoffactz]

is up ~4.4% already this year and is almost through it's 52-week high.

AEZS was about double the price it currently is when the S&P Biotech ETF was trading around its current price in Feb. of last year. Gilles scooped the assets right at the bottom.

"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels." CZO news release

Full details of the AEZS/CZO transaction expected around Jan. 31, 2024.

[prophetoffactz]

43% move in biotech of the bottom about two months ago. Then people start looking at what hasn't moved yet... @Gantosj · 1h  

[prophetoffactz]

That was quick... New 52-week high for the S&P Biotech ETF. One thing the merger should do is put CZO on the radar. It gets CZO off the TSX-V. It gets it on the NASDAQ and TSX. HC Wainwright already covers AEZS. Research Capital and Bloom Burton are involved in the transaction and could follow with analyst coverage. It doubles the size of CZO as a merger of equals. Assuming HC Wainwright'

[prophetoffactz]

People here think Gilles controls the US Federal Reserve and interest rates. It's not true. $XBI is just an Inverse derivative of Fed Rate Expectations

[prophetoffactz]

Best two months for biotech ever... Gilles purchase of AEZS could be epic - right at the bottom before the historic move. @LifeSciVC · 3h